Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Avalon GloboCare ( (ALBT) ).
On June 23, 2025, Avalon GloboCare Corp. entered into a definitive agreement with Qi Diagnostics Limited and Q&A Distribution, LLC to co-develop a volatile organic compound breathalyzer for detecting THC. The project involves four milestones, with Q&A Distribution making structured payments to Qi Diagnostics for each milestone. Qi Diagnostics will retain control over the intellectual property, while Q&A will gain passive financial interests in the intellectual property rights as milestones are completed. This collaboration aims to provide a real-time, non-invasive cannabis detection solution to enhance public safety and support law enforcement and workplace safety.
More about Avalon GloboCare
Avalon GloboCare Corp. is a developer of precision diagnostic consumer products and advances intellectual property in cellular therapy. The company is currently marketing the KetoAir™ breathalyzer device, owned and manufactured by Qi Diagnostics Limited, and plans to develop additional diagnostic uses of the breathalyzer technology. Avalon also owns and operates commercial real estate.
Average Trading Volume: 37,905
Technical Sentiment Signal: Sell
Current Market Cap: $7.31M
See more data about ALBT stock on TipRanks’ Stock Analysis page.